#BEGIN_DRUGCARD DB00064

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Megatope (IsoTex Diagnostics)

# CAS_Registry_Number:
9048-49-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C2936H4624N786O889S41

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>DB00064 sequence
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAE
NCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLP
KLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTK
VHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA
DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKC
CAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVST
PTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTES
LVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKAT
KEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following intravenous injection, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times

# Dosage_Forms:
Not Available

# Drug_Category:
Imaging Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.395

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
M12523

# Generic_Name:
Serum albumin iodonated

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For determination of total blood and plasma volumes

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
64

# Mechanism_Of_Action:
Serum albumin acts as a high molecular weight, very soluble osmolyte

# Melting_Point:
62 Â°C

# Molecular_Weight_Avg:
66472.2000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1HA2

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164752827

# Pharmacology:
Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00064

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
BIOD00089
BTD00089

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
P02768

# SwissProt_Name:
ALBU_HUMAN

# Synonyms:
Serum albumin precursor

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2011-09-03 17:04:00 -0600

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
5.67

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16441928	Cano NJ, Saingra Y, Dupuy AM, Lorec-Penet AM, Portugal H, Lairon D, Cristol JP, Come A, Le Brun A, Atlan P, Leverve XM: Intradialytic parenteral nutrition: comparison of olive oil versus soybean oil-based lipid emulsions. Br J Nutr. 2006 Jan;95(1):152-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17378158	Wang L, Li CM, Rudolf M, Curcio CA, Peng D, Liu X, Zeng S: [Gene expression of apolipoprotein and lipids synthesis and secretion in RPE-J cells] Yan Ke Xue Bao. 2006 Dec;22(4):244-51.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
APOE

# Drug_Target_1_GenBank_ID_Gene:
M12529

# Drug_Target_1_GenBank_ID_Protein:
178849

# Drug_Target_1_GeneCard_ID:
APOE

# Drug_Target_1_Gene_Name:
APOE

# Drug_Target_1_Gene_Sequence:
>954 bp
ATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTG
GAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGC
GGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACA
CTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAAGTCACCCAAGAACTGAGGGCG
CTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTG
ACCCCGGTAGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGACGGCGCAGGCC
CGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTG
CAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGC
AAGCTGCGTAAGCGGCTCCTCCGCGATCCCGATGACCTGCAGAAGCGCCTGGCAGTGTAC
CAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGG
CCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCG
CTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGC
AGTCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAG
CTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAG
AGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAG
GTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
10520737	Freitas EM, Zhang WJ, Lalonde JP, Tay GK, Gaudieri S, Ashworth LK, Van Bockxmeer FM, Dawkins RL: Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene: PEREC1. DNA Seq. 1998;9(2):89-100.
10850798	Segelke BW, Forstner M, Knapp M, Trakhanov SD, Parkin S, Newhouse YM, Bellamy HD, Weisgraber KH, Rupp B: Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding. Protein Sci. 2000 May;9(5):886-97.
12864777	Miserez AR, Scharnagl H, Muller PY, Mirsaidi R, Stahelin HB, Monsch A, Marz W, Hoffmann MM: Apolipoprotein E3Basel: new insights into a highly conserved protein region. Eur J Clin Invest. 2003 Aug;33(8):677-85.
12966036	Morabia A, Cayanis E, Costanza MC, Ross BM, Flaherty MS, Alvin GB, Das K, Gilliam TC: Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors. Hum Mol Genet. 2003 Nov 1;12(21):2733-43. Epub 2003 Sep 9.
1674745	Lohse P, Mann WA, Stein EA, Brewer HB Jr: Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J Biol Chem. 1991 Jun 5;266(16):10479-84.
2063194	Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA: Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 1991 Jun 28;252(5014):1817-22.
2556398	Wardell MR, Weisgraber KH, Havekes LM, Rall SC Jr: Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem. 1989 Dec 15;264(35):21205-10.
2760009	Maeda H, Nakamura H, Kobori S, Okada M, Niki H, Ogura T, Hiraga S: Molecular cloning of a human apolipoprotein E variant: E5 (Glu3----Lys3). J Biochem (Tokyo). 1989 Apr;105(4):491-3.
2987927	Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM: Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A. 1985 May;82(10):3445-9.
3243553	Emi M, Wu LL, Robertson MA, Myers RL, Hegele RA, Williams RR, White R, Lalouel JM: Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics. 1988 Nov;3(4):373-9.
3283935	Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622-30.
3947350	Cardin AD, Hirose N, Blankenship DT, Jackson RL, Harmony JA, Sparrow DA, Sparrow JT: Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun. 1986 Jan 29;134(2):783-9.
6325438	Zannis VI, McPherson J, Goldberger G, Karathanasis SK, Breslow JL: Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem. 1984 May 10;259(9):5495-9.
6327682	McLean JW, Elshourbagy NA, Chang DJ, Mahley RW, Taylor JM: Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. J Biol Chem. 1984 May 25;259(10):6498-504.
6897404	Breslow JL, McPherson J, Nussbaum AL, Williams HW, Lofquist-Kahl F, Karathanasis SK, Zannis VI: Identification and DNA sequence of a human apolipoprotein E cDNA clone. J Biol Chem. 1982 Dec 25;257(24):14639-41.
7068630	Rall SC Jr, Weisgraber KH, Mahley RW: Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982 Apr 25;257(8):4171-8.
7833947	de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM: Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4(3):178-94.
8287539	Richard P, Thomas G, de Zulueta MP, De Gennes JL, Thomas M, Cassaigne A, Bereziat G, Iron A: Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. Clin Chem. 1994 Jan;40(1):24-9.
8346443	Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921-3.
8488843	van den Maagdenberg AM, Weng W, de Bruijn IH, de Knijff P, Funke H, Smelt AH, Gevers Leuven JA, van't Hooft FM, Assmann G, Hofker MH, et al.: Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. Am J Hum Genet. 1993 May;52(5):937-46.
8756331	Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH: Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol. 1996 Aug;3(8):718-22.
9360638	Kang AK, Jenkins DJ, Wolever TM, Huff MW, Maguire GF, Connelly PW, Hegele RA: Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease. Mutat Res. 1997 Sep;382(1-2):57-65.

# Drug_Target_1_HGNC_ID:
HGNC:613

# Drug_Target_1_HPRD_ID:
00135

# Drug_Target_1_ID:
1932

# Drug_Target_1_Locus:
19q13.2

# Drug_Target_1_Molecular_Weight:
36155

# Drug_Target_1_Name:
Apolipoprotein E

# Drug_Target_1_Number_of_Residues:
317

# Drug_Target_1_PDB_ID:
1NFN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01442	Apolipoprotein

# Drug_Target_1_Protein_Sequence:
>Apolipoprotein E precursor
MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQT
LSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQA
RLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVY
QAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMG
SRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEK
VQAAVGTSAAPVPSDNH

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues

# Drug_Target_1_SwissProt_ID:
P02649

# Drug_Target_1_SwissProt_Name:
APOE_HUMAN

# Drug_Target_1_Synonyms:
Apo-E
Apolipoprotein E precursor

# Drug_Target_1_Theoretical_pI:
5.42

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10361047	Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB: Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999 Jul;20(13):954-9.
10903648	Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000 Jul 22;321(7255):199-204.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9200475	Grehan S, Uhlar CM, Sim RB, Herbert J, Whitehead AS: Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J Immunol. 1997 Jul 1;159(1):369-78.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SAA1

# Drug_Target_2_GenBank_ID_Gene:
M10906

# Drug_Target_2_GenBank_ID_Protein:
337748

# Drug_Target_2_GeneCard_ID:
SAA1

# Drug_Target_2_Gene_Name:
SAA1

# Drug_Target_2_Gene_Sequence:
>369 bp
ATGAAGCTTCTCACGGGCCTGGTTTTCTGCTCCTTGGTCCTGGGTGTCAGCAGCCGAAGC
TTCTTTTCGTTCCTTGGCGAGGCTTTTGATGGGGCTCGGGACATGTGGAGAGCCTACTCT
GACATGAGAGAAGCCAATTACATCGGCTCAGACAAATACTTCCATGCTCGGGGGAACTAT
GATGCTGCCAAAAGGGGACCTGGGGGTGTCTGGGCTGCAGAAGCGATCAGCGATGCCAGA
GAGAATATCCAGAGATTCTTTGGCCATGGTGCGGAGGACTCGCTGGCTGATCAGGCTGCC
AATGAATGGGGCAGGAGTGGCAAAGACCCCAATCACTTCCGACCTGCTGGCCTGTCTGAG
AAATACTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1546977	Beach CM, De Beer MC, Sipe JD, Loose LD, De Beer FC: Human serum amyloid A protein. Complete amino acid sequence of a new variant. Biochem J. 1992 Mar 1;282 ( Pt 2):615-20.
1656519	Betts JC, Edbrooke MR, Thakker RV, Woo P: The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand J Immunol. 1991 Oct;34(4):471-82.
1971508	Steinkasserer A, Weiss EH, Schwaeble W, Linke RP: Heterogeneity of human serum amyloid A protein. Five different variants from one individual demonstrated by cDNA sequence analysis. Biochem J. 1990 May 15;268(1):187-93.
2890635	Woo P, Sipe J, Dinarello CA, Colten HR: Structure of a human serum amyloid A gene and modulation of its expression in transfected L cells. J Biol Chem. 1987 Nov 15;262(32):15790-5.
3183061	Kluve-Beckerman B, Dwulet FE, Benson MD: Human serum amyloid A. Three hepatic mRNAs and the corresponding proteins in one person. J Clin Invest. 1988 Nov;82(5):1670-5.
3442653	Prelli F, Pras M, Frangione B: Degradation and deposition of amyloid AA fibrils are tissue specific. Biochemistry. 1987 Dec 15;26(25):8251-6.
3800865	Kluve-Beckerman B, Long GL, Benson MD: DNA sequence evidence for polymorphic forms of human serum amyloid A (SAA). Biochem Genet. 1986 Dec;24(11-12):795-803.
3839415	Sipe JD, Colten HR, Goldberger G, Edge MD, Tack BF, Cohen AS, Whitehead AS: Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry. 1985 Jun 4;24(12):2931-6.
7115671	Parmelee DC, Titani K, Ericsson LH, Eriksen N, Benditt EP, Walsh KA: Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoprotein. Biochemistry. 1982 Jul 6;21(14):3298-303.

# Drug_Target_2_HGNC_ID:
HGNC:10513

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3866

# Drug_Target_2_Locus:
11p15.1

# Drug_Target_2_Molecular_Weight:
13532

# Drug_Target_2_Name:
Serum amyloid A protein

# Drug_Target_2_Number_of_Residues:
122

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00277	SAA

# Drug_Target_2_Protein_Sequence:
>Serum amyloid A protein
MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNY
DAAKRGPGGVWAAEAISDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPE
KY

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
Major acute phase reactant. Apolipoprotein of the HDL complex

# Drug_Target_2_SwissProt_ID:
P02735

# Drug_Target_2_SwissProt_Name:
SAA_HUMAN

# Drug_Target_2_Synonyms:
SAA
Serum amyloid A protein precursor

# Drug_Target_2_Theoretical_pI:
6.79

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
AMBP

# Drug_Target_3_GenBank_ID_Gene:
X54816

# Drug_Target_3_GenBank_ID_Protein:
825614

# Drug_Target_3_GeneCard_ID:
AMBP

# Drug_Target_3_Gene_Name:
AMBP

# Drug_Target_3_Gene_Sequence:
>1059 bp
ATGAGGAGCCTCGGGGCCCTGCTCTTGCTGCTGAGCGCCTGCCTGGCGGTGAGCGCTGGC
CCTGTGCCAACGCCGCCCGACAACATCCAAGTGCAGGAAAACTTCAATATCTCTCGGATC
TATGGGAAGTGGTACAACCTGGCCATCGGTTCCACCTGCCCCTGGCTGAAGAAGATCATG
GACAGGATGACAGTGAGCACGCTGGTGCTGGGAGAGGGCGCTACAGAGGCGGAGATCAGC
ATGACCAGCACTCGTTGGCGGAAAGGTGTCTGTGAGGAGACGTCTGGAGCTTATGAGAAA
ACAGATACTGATGGGAAGTTTCTCTATCACAAATCCAAATGGAACATAACCATGGAGTCC
TATGTGGTCCACACCAACTATGATGAGTATGCCATTTTCCTGACCAAGAAATTCAGCCGC
CATCATGGACCCACCATTACTGCCAAGCTCTACGGGCGGGCGCCGCAGCTGAGGGAAACT
CTCCTGCAGGACTTCAGAGTGGTTGCCCAGGGTGTGGGCATCCCTGAGGACTCCATCTTC
ACCATGGCTGACCGAGGTGAATGTGTCCCTGGGGAGCAGGAACCAGAGCCCATCTTAATC
CCGAGAGTCCGGAGGGCTGTGCTACCCCAAGAAGAGGAAGGATCAGGGGGTGGGCAACTG
GTAACTGAAGTCACCAAGAAAGAAGATTCCTGCCAGCTGGGCTACTCGGCCGGTCCCTGC
ATGGGAATGACCAGCAGGTATTTCTATAATGGTACATCCATGGCCTGTGAGACTTTCCAG
TACGGCGGCTGCATGGGCAACGGTAACAACTTCGTCACAGAAAAGGAGTGTCTGCAGACC
TGCCGAACTGTGGCGGCCTGCAATCTCCCCATAGTCCGGGGCCCCTGCCGAGCCTTCATC
CAGCTCTGGGCATTTGATGCTGTCAAGGGGAAGTGCGTCCTCTTCCCCTACGGGGGCTGC
CAGGGCAACGGGAACAAGTTCTACTCAGAGAAGGAGTGCAGAGAGTACTGCGGTGTCCCT
GGTGATGGTGATGAGGAGCTGCTGCGCTTCTCCAACTGA

# Drug_Target_3_General_Function:
Involved in transporter activity

# Drug_Target_3_General_References:
10631976	Berggard T, Cohen A, Persson P, Lindqvist A, Cedervall T, Silow M, Thogersen IB, Jonsson JA, Enghild JJ, Akerstrom B: Alpha1-microglobulin chromophores are located to three lysine residues semiburied in the lipocalin pocket and associated with a novel lipophilic compound. Protein Sci. 1999 Dec;8(12):2611-20.
11058759	Akerstrom B, Logdberg L, Berggard T, Osmark P, Lindqvist A: alpha(1)-Microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta. 2000 Oct 18;1482(1-2):172-84.
1694784	Escribano J, Lopex-Otin C, Hjerpe A, Grubb A, Mendez E: Location and characterization of the three carbohydrate prosthetic groups of human protein HC. FEBS Lett. 1990 Jun 18;266(1-2):167-70.
1696200	Diarra-Mehrpour M, Bourguignon J, Sesboue R, Salier JP, Leveillard T, Martin JP: Structural analysis of the human inter-alpha-trypsin inhibitor light-chain gene. Eur J Biochem. 1990 Jul 20;191(1):131-9.
1708673	Vetr H, Gebhard W: Structure of the human alpha 1-microglobulin-bikunin gene. Biol Chem Hoppe Seyler. 1990 Dec;371(12):1185-96.
1714898	Escribano J, Grubb A, Calero M, Mendez E: The protein HC chromophore is linked to the cysteine residue at position 34 of the polypeptide chain by a reduction-resistant bond and causes the charge heterogeneity of protein HC. J Biol Chem. 1991 Aug 25;266(24):15758-63.
1898736	Enghild JJ, Salvesen G, Hefta SA, Thogersen IB, Rutherfurd S, Pizzo SV: Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem. 1991 Jan 15;266(2):747-51.
2408638	Reisinger P, Hochstrasser K, Albrecht GJ, Lempart K, Salier JP: Human inter-alpha-trypsin inhibitor: localization of the Kunitz-type domains in the N-terminal part of the molecule and their release by a trypsin-like proteinase. Biol Chem Hoppe Seyler. 1985 May;366(5):479-83.
2428011	Traboni C, Cortese R: Sequence of a full length cDNA coding for human protein HC (alpha 1 microglobulin). Nucleic Acids Res. 1986 Aug 11;14(15):6340.
2430261	Kaumeyer JF, Polazzi JO, Kotick MP: The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-alpha-trypsin inhibitor also encodes alpha-1-microglobulin (protein HC). Nucleic Acids Res. 1986 Oct 24;14(20):7839-50.
3890890	Morii M, Travis J: The reactive site of human inter-alpha-trypsin inhibitor is in the amino-terminal half of the protein. Biol Chem Hoppe Seyler. 1985 Jan;366(1):19-21.
6164372	Takagi T, Takagi K, Kawai T: Complete amino acid sequence of human alpha 1-microglobulin. Biochem Biophys Res Commun. 1981 Feb 27;98(4):997-1001.
6171497	Hochstrasser K, Schonberger OL, Rossmanith I, Wachter E: Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor, V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe Seylers Z Physiol Chem. 1981 Oct;362(10):1357-62.
6198962	Lopez Otin C, Grubb AO, Mendez E: The complete amino acid sequence of human complex-forming glycoprotein heterogeneous in charge (protein HC) from one individual. Arch Biochem Biophys. 1984 Feb 1;228(2):544-54.
7506257	Calero M, Escribano J, Grubb A, Mendez E: Location of a novel type of interpolypeptide chain linkage in the human protein HC-IgA complex (HC-IgA) and identification of a heterogeneous chromophore associated with the complex. J Biol Chem. 1994 Jan 7;269(1):384-9.
7513643	Morelle W, Capon C, Balduyck M, Sautiere P, Kouach M, Michalski C, Fournet B, Mizon J: Chondroitin sulphate covalently cross-links the three polypeptide chains of inter-alpha-trypsin inhibitor. Eur J Biochem. 1994 Apr 15;221(2):881-8.
7682553	Enghild JJ, Salvesen G, Thogersen IB, Valnickova Z, Pizzo SV, Hefta SA: Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem. 1993 Apr 25;268(12):8711-6.
9566199	Xu Y, Carr PD, Guss JM, Ollis DL: The crystal structure of bikunin from the inter-alpha-inhibitor complex: a serine protease inhibitor with two Kunitz domains. J Mol Biol. 1998 Mar 13;276(5):955-66.

# Drug_Target_3_HGNC_ID:
HGNC:453

# Drug_Target_3_HPRD_ID:
01467

# Drug_Target_3_ID:
1200

# Drug_Target_3_Locus:
9q32-q33

# Drug_Target_3_Molecular_Weight:
39000

# Drug_Target_3_Name:
AMBP protein

# Drug_Target_3_Number_of_Residues:
352

# Drug_Target_3_PDB_ID:
1BIK

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00014	Kunitz_BPTI
PF00061	Lipocalin

# Drug_Target_3_Protein_Sequence:
>AMBP protein precursor [Contains: Alpha-1-microglobulin
MRSLGALLLLLSACLAVSAGPVPTPPDNIQVQENFNISRIYGKWYNLAIGSTCPWLKKIM
DRMTVSTLVLGEGATEAEISMTSTRWRKGVCEETSGAYEKTDTDGKFLYHKSKWNITMES
YVVHTNYDEYAIFLTKKFSRHHGPTITAKLYGRAPQLRETLLQDFRVVAQGVGIPEDSIF
TMADRGECVPGEQEPEPILIPRVRRAVLPQEEEGSGGGQLVTEVTKKEDSCQLGYSAGPC
MGMTSRYFYNGTSMACETFQYGGCMGNGNNFVTEKECLQTCRTVAACNLPIVRGPCRAFI
QLWAFDAVKGKCVLFPYGGCQGNGNKFYSEKECREYCGVPGDGDEELLRFSN

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-19

# Drug_Target_3_Specific_Function:
Inter-alpha-trypsin inhibitor, present in plasma and urine, inhibits trypsin, plasmin, and lysosomal granulocytic elastase

# Drug_Target_3_SwissProt_ID:
P02760

# Drug_Target_3_SwissProt_Name:
AMBP_HUMAN

# Drug_Target_3_Synonyms:
AMBP protein precursor

# Drug_Target_3_Theoretical_pI:
6.15

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00064
